Inflammatory breast cancer (IBC) is a rare type of breast cancer. Only about 2-4% of breast cancers are considered IBC. IBC is, by definition, diagnosed at stage III or stage IV (metastatic). IBC usually does not involve a breast lump and is aggressive.
Because IBC is rare, studying it in clinical trials can be difficult. Visit the links below to learn more about research and clinical trials for metastatic IBC.
Learn About IBC
- Inflammatory Breast Cancer Research Foundation: Learn about symptoms, diagnosis, treatment, and more
- IBC Network Foundation: The IBC Network Foundation funds research into IBC and provides other resources for patients
Recent Metastatic Inflammatory Breast Cancer Research
- Dana-Farber Cancer Institute (video series): Learn about IBC by viewing these videos from the 2024 Inflammatory Breast Cancer Program Patient Forum held at Dana-Farber
- Breast Cancer Research Foundation: Researchers are studying IBC in the lab and in clinical trials
- MD Anderson (video): MD Anderson researchers Drs. Rachel Layman and Bora Lim discuss research and clinical trials for IBC (Clinical trials for IBC are discussed at the 9-, 13-, and 16-minute marks)
MBC Clinical Trials
- Metastatic Trial Search: Trials Specifically for People with Metastatic Inflammatory Breast Cancer
- Metastatic Trial Search: Trials for Which People with Metastatic Inflammatory Breast Cancer Are Eligible
Last Modified on November 3, 2025